Gene therapy market seen reaching $1.44 billion by 2030

The nucleic acid-based gene therapy market is projected to rise from $0.97 billion in 2026 to $1.44 billion by 2030, according to The Business Research Company. The outlook is being driven by CRISPR adoption, rare-disease demand, and growing public and private funding for genetic medicine.

Why it matters: - Nucleic acid-based gene therapy is moving from a niche research area toward a larger commercial market for rare disease, oncology and precision medicine treatments. - The market outlook points to rising demand for therapies that target the genetic root of disease, which could expand treatment options where few exist today. - Public and private funding is helping push research, clinical trials and manufacturing capacity forward.

What happened: - The Business Research Company projected the nucleic acid-based gene therapy market will reach $1.44 billion by 2030. - The forecast implies a 10.4% compound annual growth rate through 2030. - The market is estimated at $0.97 billion in 2026, up from $0.88 billion in 2025. - North America was the largest regional market in 2025. - Western Europe ranked second.

The details: - The report links 2025-2026 growth to advances in molecular biology, better understanding of genetic disease mechanisms, more gene therapy clinical trials, increased biotech research investment and early regulatory approvals. - Future growth is expected to come from CRISPR-based therapies, rare-disease treatments, new gene-therapy production facilities, personalized oncology therapies and public and private funding. - The report expects stronger use of RNA-based therapeutics, wider use of viral and non-viral delivery systems, better targeted gene editing, more personalized genetic therapies and a greater focus on precision medicine. - Nucleic acid-based gene therapy uses DNA or RNA to alter or regulate gene expression inside a patient’s cells. - The approach aims to treat or prevent disease by targeting the genetic causes of malfunctioning cells. - The report covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa in addition to North America and Western Europe. - A free sample of the report is available through the company’s sample page. - The full report is available on The Business Research Company’s report page.

Between the lines: - The forecast suggests gene therapy is entering a more mature phase, with funding and manufacturing capability becoming as important as scientific progress. - The NIH allocated more than $140 million in July 2023 to accelerate genome editing technologies for rare neurological and blood disorders, up from $92 million in 2022. - That jump shows how government support is increasingly aligned with therapies that address hard-to-treat genetic conditions.

What's next: - The market is expected to keep expanding through 2030 as CRISPR, RNA therapeutics and precision medicine tools gain broader use. - Continued capital spending on production facilities and research infrastructure is likely to shape which companies can scale fastest. - More clinical trial activity and regulatory decisions could further define the pace of commercial adoption.

The bottom line: - The Business Research Company sees nucleic acid-based gene therapy as a fast-growing market with a clear path to broader clinical and commercial relevance by 2030.